Skip to content
Shameless Cloning

Search Shameless Cloning

Search superinvestors, stocks, insiders and members of Congress

Q2 2026 13F · SEC CIK 1274413

Sectoral Asset Management Inc

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value
$143.3M
Reported positions
82
Top holdings a year, 3 yrs
+9.6%
Assets under management
$331.4M

Sectoral Asset Management Inc is a hedge fund that reported 82 positions worth $143.3M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Contineum Therapeutics Inc (CTNM, 8.3%), Shoulder Innovations Inc (SI, 6.1%), Eli Lilly & Co (LLY, 5.3%). A portfolio copying its top holdings returned 9.6% a year over the last 3 years, against 20.4% for the S&P 500.

Sectoral Asset Management Inc holdings largest 50 of 82 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Sectoral Asset Management Inc 13F holdings
Stock% of 13F valueShare changeReported value
CTNMContineum Therapeutics Inc8.3%+0.0%$11.9M
SIShoulder Innovations Inc6.1%+0.0%$8.7M
LLYEli Lilly & Co5.3%+0.0%$7.6M
UNHUnitedhealth Group Inc3.8%-11.5%$5.5M
JNJJohnson & Johnson3.2%+0.0%$4.6M
ORKAOruka Therapeutics Inc2.8%—$4.0M
BNTXBiontech SE2.7%+88.9%$3.9M
24477V105Definium Therapeutics Inc2.6%—$3.7M
DXCMDexcom Inc2.4%+118.5%$3.4M
RCUSArcus Biosciences Inc.2.4%+146.0%$3.4M
AMGNAmgen Inc2.3%+0.0%$3.3M
SMMTSummit Therapeutics Inc2.2%+216.3%$3.2M
IRTCIrhythm Technologies Inc2.2%—$3.1M
ABBVAbbvie Inc2.1%+0.0%$3.1M
MRKMerck & Co Inc1.9%+0.0%$2.8M
AVBPArrivent Biopharma Inc1.9%+163.4%$2.7M
VRTXVertex Pharmaceuticals Inc1.9%-22.5%$2.7M
ARGNFArgenx SE1.8%-20.6%$2.6M
GILDGilead Sciences Inc1.8%-25.0%$2.6M
INSMInsmed Inc1.7%+18.0%$2.5M
TECXTectonic Therapeutic Inc1.7%+272.6%$2.4M
ISRGIntuitive Surgical Inc1.6%+11.4%$2.3M
IMTXImmatics NV1.6%+236.6%$2.3M
SYKStryker Corporation1.6%+21.4%$2.2M
AVTXAvalo Therapeutics Inc1.5%—$2.2M
CBIOCrescent Biopharma Inc1.5%—$2.2M
ROIVRoivant Sciences Ltd1.5%+88.0%$2.2M
IQVIqvia Hldgs Inc1.5%+30.6%$2.1M
PLSEPulse Biosciences Inc1.3%—$1.9M
DHRDanaher Corp Del1.3%+0.0%$1.8M
TMOThermo Fisher Scientific Inc1.2%+0.0%$1.8M
ABTAbbott Laboratories1.1%-29.3%$1.6M
ATECAlphatec Hldgs Inc1.1%—$1.6M
BSXBoston Scientific Corp1.1%+4.5%$1.6M
TMDXTransmedics Group Inc1.0%—$1.5M
CYTKCytokinetics1.0%—$1.4M
REGNRegeneron Pharmaceuticals0.9%-25.7%$1.4M
CVSCvs Health Corp0.9%—$1.3M
EWEdwards Lifesciences Corp0.9%-14.5%$1.3M
TRVITrevi Therapeutics Inc0.9%-11.9%$1.2M
BMYBristol-Myers Squibb Co0.8%+0.0%$1.2M
VERAVera Therapeutics Inc Class A0.8%+0.0%$1.1M
COGTCogent Biosciences Inc0.7%+20.8%$1.0M
MDTMedtronic PLC0.6%+0.0%$876K
TARSTarsus Pharmaceuticals Inc0.6%+17.9%$836K
KURAKura Oncology Inc0.5%—$784K
CNCCentene Corp Del0.5%—$770K
UTHRUnited Therapeutics Corp Del0.5%-19.9%$742K
HNGEHinge Health, Inc.0.5%—$726K
NKTRNektar Therapeutics0.5%-6.8%$706K

What Sectoral Asset Management Inc bought and sold in Q2 2026, against Q1 2026.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year
+33.7% /yr
S&P 500 +20.1%
3 years
+9.6% /yr
S&P 500 +20.4%
5 years
-1.3% /yr
S&P 500 +11.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter13F valuePositions
Q2 2026$143.3M82
Q1 2026$120.7M77
Q4 2025$124.8M74
Q3 2025$162.0M82
Q2 2025$151.5M94
Q1 2025$128.5M84
Q4 2024$149.8M86
Q3 2024$169.3M90
Q2 2024$246.1M97
Q1 2024$254.4M92
Q4 2023$232.2M104
Q3 2023$513.5M123

Questions about Sectoral Asset Management Inc's portfolio

What stocks does Sectoral Asset Management Inc own?

Sectoral Asset Management Inc's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 82 positions worth $143.3M. The largest are Contineum Therapeutics Inc (CTNM) at 8.3%, Shoulder Innovations Inc (SI) at 6.1%, Eli Lilly & Co (LLY) at 5.3%, Unitedhealth Group Inc (UNH) at 3.8% and Johnson & Johnson (JNJ) at 3.2%.

What did Sectoral Asset Management Inc buy last quarter?

In Q2 2026, Sectoral Asset Management Inc added Tectonic Therapeutic Inc (TECX) (+272.6% shares), Immatics NV (IMTX) (+236.6% shares) and Summit Therapeutics Inc (SMMT) (+216.3% shares), compared with its Q1 2026 filing.

What did Sectoral Asset Management Inc sell last quarter?

In Q2 2026, Sectoral Asset Management Inc cut from its top 50 Evommune Inc (EVMN), cut from its top 50 Mineralys Therapeutics Inc (MLYS), cut from its top 50 Alnylam Pharmaceuticals Inc (ALNY), cut from its top 50 Rapport Therapeutics Inc (RAPP), cut from its top 50 Syndax Pharmaceuticals Inc (SNDX), Abbott Laboratories (ABT) (-29.3% shares), Regeneron Pharmaceuticals (REGN) (-25.7% shares) and Gilead Sciences Inc (GILD) (-25.0% shares), compared with its Q1 2026 filing.

How has Sectoral Asset Management Inc's portfolio performed?

A portfolio copying Sectoral Asset Management Inc's 20 largest 13F holdings each quarter, from the day each filing was public, returned +9.6% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +33.7% against +20.1%. Over 5 years: -1.3% a year against +11.6%.

When is Sectoral Asset Management Inc's next 13F filing due?

13F filings are due 45 days after each quarter ends. Sectoral Asset Management Inc's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Sectoral Asset Management Inc manage?

Sectoral Asset Management Inc reported $331.4M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $143.3M.